Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Inclusion Criteria: * Performance status (WHO) 0-2 * Histologically confirmed metastatic breast adenocarcinoma (stage IV) without any prior chemotherapy received * HER-2 overexpression 2+ or 3+ using IHC or FISH + * Measurable disease not in a prior irradiation field (no other concurrent chemotherapy agents) * No more than 25% of myeloproductive bone marrow irradiated (more than 4 weeks since prior radiotherapy and recovered) * More than 6 months since prior adjuvant or neoadjuvant chemotherapy and recovered * No prior first line chemotherapy for metastatic disease * Endocrine therapy is allowed as adjuvant or first line treatment for metastatic disease * Paraffin block from the primary tumor available in the research lab * Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3) * Adequate liver (Bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2mg/dl) * Adequate cardiac function (LVEF \> 50%) * Informed consent Exclusion Criteria: * Pregnant or nursing * Concurrent agents ketoconazole, macrolide antibiotics, zidovudine which may induce P-450 cytochrome * Positive pregnancy test * Motor or sensory neuropathy \> grade 1 according to NCIC Τoxicity Criteria * Patients with brain metastatic disease who has not been irradiated or uncontrolled brain metastatic disease after irradiation * History of allergic reaction attributed to docetaxel * Psychiatric illness or social situation that would preclude study compliance * Other concurrent uncontrolled illness. * Other invasive malignancy within the past 5 years except cured basal cell skin carcinoma and cervical carcinoma in situ